Kestra Medical TechnologiesvsEli Lilly and Company

KMTS and LLY stock compared: price, dividend, valuation and results, from SEC filings.

KMTS

Kestra Medical Technologies, Ltd.

$28.29

Value $1.7B

+0.07%
KMTS's page

LLY

Eli Lilly and Company

$1,382.75

Value $1.30T

-2.32%
LLY's page

Kestra Medical Technologies (KMTS) has a market value of $1.7B and Eli Lilly and Company (LLY) $1.30T. Over the last year, with dividends, KMTS moved +12.7% and LLY +36.2%. Dividend yield: KMTS none, LLY 0.46%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    KMTS$1.7B

    LLY$1.30T

    LLY is 787 times KMTS

  • Revenue, 12 months

    KMTS$107M

    LLY$86.5B

    LLY is 810 times KMTS

  • Net income, 12 months

    KMTS-$150M

    LLY$27.6B

  • Operating margin

    KMTS-134.5%

    LLY–

  • ROIC

    KMTS-41.7%

    LLY35.5%

    77.2 points apart

  • P/E

    KMTS–

    LLY47.3

  • Dividend yield

    KMTS0.0%

    LLY0.5%

    0.5 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

KMTS+12.7%

LLY+36.2%

80100120140DecFebAprJunAugOct
Returns by period
PeriodKMTSWith dividendsLLYWith dividends
1 year since November 17, 2025+12.7%Price +12.7%+36.2%Price +35.3%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

KMTSKestra Medical TechnologiesLLYEli Lilly and Company

Valuation

KMTSLLY
Valuation
Price$28.29$1,382.75
Market value$1.7B$1.30T
Enterprise value (EV)–$1.35T
P/E–47.3
P/E, 5-year median–49.9
P/B7.532.4
EV/EBIT–38.8
Free cash flow yield–1.5%

Results and growth

KMTSLLY
Results and growth
Revenue, 12 months$107M$86.5B
Net income, 12 months-$150M$27.6B
Free cash flow, 12 months-$123M$19.7B
Earnings per share, 12 months-$2.67$30.81
Revenue growth, year on year59.0%44.7%
Revenue growth a year, past+84.9%over 2 years+21.6%over 5 years
EPS growth a year, past–+27.6%over 5 years

Margins and returns on capital

KMTSLLY
Margins and returns on capital
Gross margin53.9%83.6%
Operating margin-134.5%–
Net margin-140.4%31.9%
ROIC-41.7%35.5%
ROE-67.0%88.6%

Balance sheet

KMTSLLY
Balance sheet
Cash$245M$4.9B
Total debt–$49.5B
Net debt / EBITDA–1.2
Interest cover-19.0×38.9×

Dividends and buybacks

KMTSLLY
Dividends and buybacks
Dividend yield–0.5%
Dividend per share, 12 months–$6.34
Dividend growth a year, past–+15.2%over 5 years
Buyback yield–0.3%
Shareholder yield–0.8%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: KMTS or LLY

Didn't find what you were looking for?

Ask us
Which is bigger, Kestra Medical Technologies or Eli Lilly and Company?

By market value, Eli Lilly and Company ($1.30T) is about 786.8 times Kestra Medical Technologies ($1.7B), at today's prices.

How did KMTS and LLY stock do over the last 1 years?

Since November 17, 2025, KMTS's price moved +12.7% and LLY's +35.3%. With dividends: KMTS +12.7% (+12.7% a year), LLY +36.2% (+36.2% a year). Past returns do not predict future ones.

Which pays the higher dividend, KMTS or LLY?

The dividend yield at today's price is none for Kestra Medical Technologies and 0.46% for Eli Lilly and Company. Over the last twelve months they paid – and $6.34 per share.

Which has the higher profit margins, Kestra Medical Technologies or Eli Lilly and Company?

Over the last twelve months, the net margin was -140.4% for Kestra Medical Technologies and 31.9% for Eli Lilly and Company, and the operating margin -134.5% and –. Revenue was $107M and $86.5B.

Which is the better investment, Kestra Medical Technologies or Eli Lilly and Company?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.